Citations

Clear

3042 citation(s) found for "Kumar, S".

Intraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort
Howlett, Lindsay N. , Fadadu, Priyal , Grcevich, Leah, Fought, Angela J. , McGree, Michaela E. , Giannini, Andrea , Butler, Kristina , Marnholtz, Amanda A., Haddock, Michael G. , Garda, Allison E. , Dowdy, Sean C. , Kumar, Amanika , Fadadu, Priyal P , Grcevich, Leah O, Butler, Kristina A., Garda, Allison E , Kumar, Amanika , Tortorella, Lucia , Langstraat, Carrie

Mayo Clinic

Cancers | October 28, 2024 | Volume: 16 | Issue: 21 | Pages: 3628

10.3390/cancers16213628 | PMID 39518067 Get It

Background/Objectives: Our objective was to describe the use of intraoperative radiation therapy (IORT) for the treatment of recurrent/persistent cervical or endometrial cancer and assess predictors of postoperative complications and 3-year mortality. Methods: In this multi-site retrospective study, data were abstracted for recurrent/persistent endometrial or cervical cancer patients who underwent IORT from June 2004 to May 2021. Complications were graded on the six-point Accordion scale. Variables associated with complications were analyzed with univariate logistic regression, while variables associated with death within 3 years were analyzed with Cox proportional hazards modeling. Survival was analyzed with the Kaplan–Meier method. Results: Eighty patients had planned IORT for recurrent/persistent endometrial (n = 35) or cervical cancer (n = 45). The mean age of the cohort was 56.8 years (SD = 13.7), and the median disease-free interval from primary disease to recurrence was 20.0 months (IQR 10.0–63.1). The overall survival at 3 years was 48.6% (95% CI: 38.3–61.6%) with a median survival of 2.8 years. Within 30 days postoperative, 16 patients (20.1%) had grade 3–5 complications and one death (1.3%) occurred. Factors associated with grade 3+ complication included ECOG PS 2–3 (OR 18.00, p = 0.04), neoadjuvant chemotherapy and/or immunotherapy (OR 6.98, p < 0.01), and pelvic sidewall involvement (OR 8.80, p = 0.04). Factors associated with death within 3 years of surgery included ECOG PS 2–3 (HR 8.97, p < 0.01), neoadjuvant chemotherapy and/or immunotherapy (HR 2.34, p = 0.03), whether exenteration was performed (HR 2.64, p = 0.01), and positive resection margin (HR 3.37, p < 0.01). Conclusions: In well-selected patients, IORT is a feasible and safe option for the treatment of recurrent/persistent gynecologic malignancy with an appreciable survival benefit.
Pemetrexed‐carboplatin salvage therapy in advanced thyroid cancers
Lee, K. , Morris, John C. , Peskey, Candy S , Hilger, Crystal, Bible, Keith C. , Ryder, Mabel , Lee, Kenzie K , Kumar, Aditi, Peskey, Candy, Hilger, Crystal R, Ryder, Mabel , Morris, John C., Kumar, Aditi , Chintakuntlawar, Ashish V.

Mayo Clinic

Head & Neck | October 28, 2024 | Volume: 47 | Issue: 3 | Pages: 813-821

10.1002/hed.27940 | PMID 39462887 Get It

Abstract Background The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments. Methods We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed‐carboplatin (PC) at Mayo Clinic since 2019. Results Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC. Patients with DTC ( n = 7) had durable responses with a median progression‐free survival of 29 months. One responder included a patient with ATC whose disease progressed following pembrolizumab/axitinib, lenvatinib, and dabrafenib/trametinib. On this fourth line treatment, the patient remains on therapy to date, over 12 months after initial response. Conclusions This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
S1939 The Evolving Landscape of Drug Induced Liver Injury (DILI): Tracking New Drug Culprits
Maddineni, Gautam , Choday, Silpa, Vikash, Fnu , Pulakurthi, Yashwitha Sai, Kumar, Vikash , Shah, Mihir P., Chakinala, Raja Chandra , Boppana, Vaishnavi, Brahmbhatt, Bhaumik , Pan, Chun‐Wei , Shah, Mihir Prakash

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1387-S1388

10.14309/01.ajg.0001037124.81921.b2 Get It

S1176 Readmission Rates in the Inflammatory Bowel Disease Population After Coronary Artery Bypass Grafting: A Nationwide Analysis
Bhagat, Umesh , Kharel, Archana, Almomani, Ashraf , Saab, Omar, Aggarwal, Manik , Kumar, Prabhat , Kharel, Archana, Agrawal, Ankit , Chandna, Sanya , Bickston, Stephen J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S836-S836

10.14309/01.ajg.0001034072.58021.ed Get It

S1177 Outcomes in Inflammatory Bowel Disease in Patients Undergoing Coronary Artery Bypass Grafting: A Nationwide Analysis
Kumar, Prabhat , Bhagat, Umesh , Kharel, Archana, Agrawal, Ankit, Aggarwal, Manik , Kharel, Archana, Agrawal, Ankit, Bickston, Stephen J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S836-S837

10.14309/01.ajg.0001034076.34474.0c Get It

A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?
Chang, Marvin G. , Ripoll, Juan G. , Lopez, Ernesto , Krishnan, Kumar , Bittner, Edward A. , Ripoll, Juan G , Lopez, Ernesto

Mayo Clinic

Journal of Clinical Medicine | October 23, 2024 | Volume: 13 | Issue: 21 | Pages: 6336

10.3390/jcm13216336 | PMID 39518474 Get It

Background: The increased popularity and ubiquitous use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of diabetes, heart failure, and obesity has led to significant concern for increased risk for perioperative aspiration, given their effects on delayed gastric emptying. This concern is highlighted by many major societies that have published varying guidance on the perioperative management of these medications, given limited data. We conducted a scoping review of the available literature regarding the aspiration risk and aspiration/regurgitant events related to GLP-1 RAs. Methods: A librarian-assisted search was performed using five electronic medical databases (PubMed, Embase, and Web of Science Platform Databases, including Web of Science Core Collection, KCI Korean Journal Database, MEDLINE, and Preprint Citation Index) from inception through March 2024 for articles that reported endoscopic, ultrasound, and nasogastric evaluation for increased residual gastric volume retained food contents, as well as incidences of regurgitation and aspiration events. Two reviewers independently screened titles, abstracts, and full text of articles to determine eligibility. Data extraction was performed using customized fields established a priori within a systematic review software system. Results: Of the 3712 citations identified, 24 studies met eligibility criteria. Studies included four prospective, six retrospective, five case series, and nine case reports. The GLP-1 RAs reported in the studies included semaglutide, liraglutide, lixisenatide, dulaglutide, tirzepatide, and exenatide. All studies, except one case report, reported patients with confounding factors for retained gastric contents and aspiration, such as a history of diabetes, cirrhosis, hypothyroidism, psychiatric disorders, gastric reflux, Barrett’s esophagus, Parkinson’s disease, dysphagia, obstructive sleep apnea, gastric polyps, prior abdominal surgeries, autoimmune diseases, pain, ASA physical status classification, procedural factors (i.e., thyroid surgery associated with risk for nausea, ketamine associated with nausea and secretions), and/or medications associated with delayed gastric emptying (opioids, anticholinergics, antidepressants, beta-blockers, calcium channel blockers, DPP-IV inhibitors, and antacids). Of the eight studies (three prospective and five retrospective) that evaluated residual contents in both GLP-1 users and non-users, seven studies (n = 7/8) reported a significant increase in residual gastric contents in GLP-1 users compared to non-users (19–56% vs. 5–20%). In the three retrospective studies that evaluated for aspiration events, there was no significant difference in aspiration events, with one study reporting aspiration rates of 4.8 cases per 10,000 in GLP-1 RA users compared to 4.6 cases per 10,000 in nonusers and the remaining two studies reporting one aspiration event in the GLP-1 RA user group and none in the non-user group. In one study that evaluated for regurgitation or reflux by esophageal manometry and pH, there was no significant difference in reflux episodes but a reduction in gastric acidity in the GLP-1 RA user group compared to the non-user group. Conclusions: There is significant variability in the findings reported in the studies, and most of these studies include confounding factors that may influence the association between GLP-1 RAs and an increased risk of aspiration and related events. While GLP-1 RAs do increase residual gastric contents in line with their mechanism of action, the currently available data do not suggest a significant increase in aspiration and regurgitation events associated with their use and the withholding of GLP-1 RAs to reduce aspiration and regurgitation events, as is currently recommended by many major societal guidelines. Large randomized controlled trials (RCTs) may be helpful in further elucidating the impact of GLP-1 RAs on perioperative aspiration risk.
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
Visram, Alissa , Larson, Dirk R. , Murray, David , Kyle, Robert A. , Slager, Susan L. , Kumar, Shaji , Vachon, Celine M. , Larson, Dirk , Norman, Aaron, Dispenzieri, Angela , Slager, Susan L , Kumar, Shaji K , Vachon, Celine M. , Visram, Alissa , Norman, Aaron D. , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 22, 2024 | Volume: 145 | Issue: 3 | Pages: 325-333

10.1182/blood.2024025415 | PMID 39437710 Get It

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant disorder. The current standard of care is not to screen for MGUS, so it is often incidentally diagnosed in the clinic. It is unknown whether the outcomes of screened vs clinically detected MGUS differ. We compared the progression risk between screened vs clinical MGUS cohorts and assessed whether the MGUS detection method affected risk prediction of established clinical factors (score). We included 379 screened MGUS cases from the Olmsted County population-based study and 1384 patients with MGUS diagnosed during routine clinical evaluation at Mayo Clinic. Median follow-up time for the screened vs clinical cohort was 26.6 and 40.1 years, respectively. Accounting for death as a competing risk, the cumulative incidence of progression at 25 years was similar in the screened (11.1% [95% confidence interval [CI], 8.3-14.8]) vs clinical (10.1% [95% CI, 8.6-11.8]) MGUS cohorts, even when stratified by sex, age, or the baseline MGUS risk score. Overall, 0.9 (95% CI, 0.6-1.2) of patients with screened MGUS vs 1.0 (95% CI, 0.9-1.2) of those with clinically detected MGUS experienced disease progression for every 100 person-years of follow-up. MGUS detection method did not modify the association between MGUS risk score and progression risk (pinteraction = 0.217) and did not add to known risk factors for progression (likelihood ratio test; P = .839). Here, we show that progression risk among patients with screened vs clinically detected heavy-chain MGUS was similar. Future studies are needed to assess whether tailored follow-up of patients with screened MGUS affects clinical outcomes.
Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α‐Catenin
Osumi, Teruko, Al‐Toubat, Mohammed , Serrano, Samuel, McKenna, Robert W., Chardon‐Robles, Jonathan, Balaji, K.C. , Al-Toubat, Mohammed , Singh, Pankaj Kumar , Shukla, Sanjeev , Singh, Pankaj K. , Mietzsch, Mario , McKenna, Robert, Krishnan, Sunil

Mayo Clinic

The Prostate | October 21, 2024 | Volume: 85 | Issue: 2 | Pages: 156-164

10.1002/pros.24812 | PMID 39428693 Get It

AbstractBackgroundThe E‐cadherin, α‐ and β‐Catenin interaction at the cell adherens junction plays a key role in cell adhesion; alteration in the expression and function of these genes are associated with disease progression in several solid tumors including prostate cancer. The membranous β‐Catenin is dynamically linked to the cellular cytoskeleton through interaction with α‐Catenin at amino acid positions threonine 120 (T120) to 151 of β‐Catenin. Nuclear presence of α‐Catenin modulates the sensitivity of cells to DNA damage. The objective of this study is to determine the role of α‐Catenin and protein kinase D1 (PrKD1) in DNA damage response.MethodsProstate cancer cells; LNCaP, LNCaP (Sh‐PrKD1; silenced PrKD1), C4‐2 and C4‐2 PrKD1 were used for various sets of experiments to determine the role of DNA damage in PrKD1 overexpression and silencing cells. These cells were treated with compound‐10 (100 nM) and Etoposide (30 µM), total cell lysates, cytosolic and nuclear fractions were prepared to observe various protein expressions. We performed single cell gel electrophoresis (COMET assay) to determine the etoposide induce DNA damage in C4‐2 and C4‐2 PrKD1 cells. The animal experiments were carried out to determine the tolerability of compound‐10 by mice and generate preliminary data on efficacy of compound‐10 in modulating the α‐Catenin and PrKD1 expressions in inhibiting tumor progression.ResultsPrKD1, a novel serine threonine kinase, phosphorylates β‐Catenin T120. In silico analysis, confirmed that T120 phosphorylation alters β‐ to α‐Catenin binding. Forced expression of PrKD1 in prostate cancer cells increased β‐ and α‐Catenin protein levels associated with reduced etoposide induced DNA damage. Downregulation of α‐Catenin abrogates the PrKD1 mitigation of DNA damage. The in vitro results were corroborated in vivo using mouse prostate cancer patient derived xenograft model by inhibition of PrKD1 kinase activity with compound‐10, a selective PrKD inhibitor, demonstrating decreased total β‐ and α‐Catenin protein levels, and β‐Catenin T120 phosphorylation.ConclusionsAlteration in DNA damage response pathways play major role in prostate cancer progression. The study identifies a novel mechanism of α‐Catenin dependent DNA damage mitigation role for PrKD1 in prostate cancer.
Extracting social support and social isolation information from clinical psychiatry notes: comparing a rule-based natural language processing system and a large language model
Patra, Braja Gopal , Lepow, Lauren , Kumar, Praneet Kasi Reddy Jagadeesh, Vekaria, Veer , Sharma, Mohit , Adekkanattu, Prakash , Fennessy, Brian , Hynes, Gavin, Landi, Isotta , Sánchez-Ruiz, Jorge A. , Ryu, Euijung , Nadkarni, Girish N. , Talati, Ardesheer , Zhang, Yiye , Charney, Alexander W. , Pathak, Jyotishman , Lepow, Lauren A , Sharma, Mohit M , Pathak, Jyotishman , Vekaria, Veer , Patra, Braja G , Sanchez-Ruiz, Jorge A , Biernacka, Joanna M. , Weissman, Myrna M. , Olfson, Mark , Mann, J. John

Mayo Clinic

Journal of the American Medical Informatics Association | October 18, 2024 | Volume: 32 | Issue: 1 | Pages: 218-226

10.1093/jamia/ocae260 | PMID 39423850 Get It

Abstract Objectives Social support (SS) and social isolation (SI) are social determinants of health (SDOH) associated with psychiatric outcomes. In electronic health records (EHRs), individual-level SS/SI is typically documented in narrative clinical notes rather than as structured coded data. Natural language processing (NLP) algorithms can automate the otherwise labor-intensive process of extraction of such information. Materials and Methods Psychiatric encounter notes from Mount Sinai Health System (MSHS, n = 300) and Weill Cornell Medicine (WCM, n = 225) were annotated to create a gold-standard corpus. A rule-based system (RBS) involving lexicons and a large language model (LLM) using FLAN-T5-XL were developed to identify mentions of SS and SI and their subcategories (eg, social network, instrumental support, and loneliness). Results For extracting SS/SI, the RBS obtained higher macroaveraged F1-scores than the LLM at both MSHS (0.89 versus 0.65) and WCM (0.85 versus 0.82). For extracting the subcategories, the RBS also outperformed the LLM at both MSHS (0.90 versus 0.62) and WCM (0.82 versus 0.81). Discussion and Conclusion Unexpectedly, the RBS outperformed the LLMs across all metrics. An intensive review demonstrates that this finding is due to the divergent approach taken by the RBS and LLM. The RBS was designed and refined to follow the same specific rules as the gold-standard annotations. Conversely, the LLM was more inclusive with categorization and conformed to common English-language understanding. Both approaches offer advantages, although additional replication studies are warranted.